It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage pharma company developing novel treatments for rare autoimmune diseases and cancer
- Lead asset KZR-616= in P2 for the treatment of lupus nephritis (LN), dermatomyositis (DM), and polymyositis (PM)
- Second asset KZR-261= entering clinical trials later this year for cancer